Please assess the completion status of the following clinical trial:

Trial Title: Cellcept for Treatment of Juvenile Neuronal Ceroid Lipofuscinosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* JNCL as determined by a characteristic clinical presentation and confirmatory genetic evidence.~* Able to walk 10 feet without assistance beyond that required due to vision impairment.~* Subjects with local treating clinician (pediatrician or neurologist) willing to conduct the trial according to the protocol, good clinical practice, and applicable regulations.~* Subjects with a parent/legal guardian willing to accompany them to all study visits, oversee study drug compliance, and monitor and report to local treating clinician/investigator and the URBC investigative personnel any signs of adversity.~Exclusion Criteria:~* Inability to tolerate oral administration of medications~* Concomitant medical condition, which, in the opinion of the local treating clinician, the parent(s)/guardian, or the URBC study investigator would place the child at greater than acceptable risk from: 1) travel by plane or car to the URBC on four occasions over the course of 22 weeks, 2) exposure to mycophenolate mofetil at protocol defined dosages for periods up to 8 weeks.~* Anticipated inability of the child (on the part of the investigator, parent/guardian, or URBC study personnel) to comply with the rigors of the protocol..~* Use of disallowed concomitant medications.~* Administration of immunosuppressive medications~* History of any prior exposure to mycophenolate mofetil~* History of hypersensitivity to mycophenolate mofetil, or any other component of the product~* History of frank gastrointestinal hemorrhage, ulceration, or melena~* White blood cell count \< 3000/μL, absolute neutrophil count (ANC) \< 1500/μL, hemoglobin \< 10g/dL, or thrombocytopenia \<100,000/μL.~* Abnormal liver function (aspartate aminotransferase (AST) or alanine aminotransferase (ALT) or bilirubin greater than 3 times the upper limit of normal)~* Pregnancy or vulnerability to engage in sexual intercourse based on report of the parent/guardian, judgment of the local treating clinician/investigator or judgment of the URBC study personnel.~* Positive Tuberculosis test~* Immunizations not up to date for age according to Centers for Disease Control guidelines

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Mycophenolate Mofetil (Type: ACTIVE_COMPARATOR): None
- Placebo liquid (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).